Assays of type I procollagen domains and collagen fragments: Problems to be solved and future trends

References

• Eriksen E F, Brixen K, Charles P. New markers of bone metabolism; clinical use in metabolic bone disease. Eur J Endocrinol 1995; 132: 251–263
   PubMed Web of Science ®Google Scholar
• Stein G S, Lian J B, Owen T A. Relationship of cell growth to the eegulation of tissue-specific gene expression during osteoblast differentiation. FASEB J 1990; 4: 3111–3123
   PubMed Web of Science ®Google Scholar
• Prockop D J, Kivirikko K I, Tuderman L, Guzman N A. The biosynthesis of collagen and its disorders. New Engl J Med 1979; 301: 12–23; 77–85
   Web of Science ®Google Scholar
• Risteli J, Niemi S, Kauppila S, Melkko J, Risteli L. Collagen propeptides as indicators of collagen assembly. Acta Orthop Scand 1995; 66: 183–188, (Suppl 266)
   Web of Science ®Google Scholar
• Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrød B. Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 1994; 179: 405–412
   PubMed Web of Science ®Google Scholar
• Smedsrød B, Melkko J, Risteli L, Risteli J. Circulating carboxyterminal propeptide of type I procollagen is cleared via the mannose receptor in liver endothelial cells. Biochem J 1990; 271: 345–350
   PubMed Web of Science ®Google Scholar
• Taubman M B, Goldberg B, Sherr C J. Radioimmunoassay for human procollagen. Science 1974; 186: 1115–1117
   PubMed Web of Science ®Google Scholar
• Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1328–1332
   PubMed Web of Science ®Google Scholar
• Pedersen B J, Bonde M. Purification of human procollagen type I carboxyl-terminal propeptide cleaved as in vivo from procollagen and used to calibrate a radioimmunoassay of the propeptide. Clin Chem 1994; 40: 811–816
   PubMed Web of Science ®Google Scholar
• Ebeling P R, Peterson J M, Riggs B L. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7: 1243–1250
   PubMed Web of Science ®Google Scholar
• Linkhart S H, Linkhart T A, Taylor A K, Wergedal J E, Bettica P, Baylink D J. Synthetic peptide-based immunoassay for amino-terminal propeptide of type I procollagen: application for evaluation of bone formation. Clin Chem 1993; 39: 2254–2260
   PubMed Web of Science ®Google Scholar
• Rasmussen H B, Teisner B, Grma J, Brixen K, Yde-Andersen E, Bollerslev J. Serum levels of fetal antigen 2 in hyperthyroidism and primary hyperparathyroidism. APMIS 1992; 100: 894–900
   PubMed Web of Science ®Google Scholar
• Price K M, Silman R, Armstrong P, Grudzinskas J G. Development of a radioimmunoassay for fetal antigen 2. Clin Chim Acta 1994; 224: 95–102
   PubMed Web of Science ®Google Scholar
• Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996; 42: 947–954
   PubMed Web of Science ®Google Scholar
• Toivonen J, Tähtelä R, Laitinen K, Risteli J, Välimäki M J. Markers of bone turnover in patients with differentiated thyroid cancer on and off thyroxine suppressive therapy, Manuscript, submitted for publication
   Google Scholar
• Sharp C A, Evans S F, Risteli L, Risteli J, Worsfold M, Davie M WJ. Effects of low and conventional dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women. Eur J Clin Invest 1996; 26: 763–771
   PubMed Web of Science ®Google Scholar
• Sharp C A, Davie M WJ, Worsfold M, Risteli L, Risteli J. Discrepant blood concentrations of type I procollagen propeptides in active Paget disease of bone. Clin Chem 1996; 42: 1121–1122
   PubMed Web of Science ®Google Scholar
• Eyre D R, Paz M A, Gallop P M. Cross-linking in collagen and elastin. Ann Rev Biochem 1994; 53: 717–748
   Web of Science ®Google Scholar
• Risteli J, Eriksen H, Risteli L, Mansell J P, Bailey A J. Pyrrolic cross-links are as abundant in human bone type I collagen as pyridinolines. J Bone Min Res 1994; 9: S186
   Google Scholar
• Hanson D A, Eyre D R. Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J Biol Chem 1996; 271: 26508–26516
   PubMed Web of Science ®Google Scholar
• Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635–640
   PubMed Web of Science ®Google Scholar
• Sassi M-L, Eriksen H, Niemi S, Mansell J, Risteli L, Risteli J. Immunochemical characterization of the assay for the human carboxyterminal telopeptide of type I collagen (ICTP) by comparison with the corresponding bovine antigen, Manuscript, submitted for publication
   Google Scholar
• Bonde M, Qvist P, Fledelius C, Riis B J, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994; 40: 2022–2025
   PubMed Web of Science ®Google Scholar
• Hanson D A, Weis M AE, Bollen A-M, Maslan S L, Singer F R, Eyre D R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7: 1251–1258
   PubMed Web of Science ®Google Scholar
• Blumsohn A C, Naylor K, Eastell R. Effect of light and -irridation on pyridinolines and telopeptide of type I collagen in urine. ClinChem 1995; 41: 1195–1197
   Google Scholar
• Robins S P. Collagen crosslinks in metabolic bone diseases. Acta Ortop Scan 1995; 66: 171–175, (Suppl 266)
   Web of Science ®Google Scholar